Going into 2025, we expect pharma brands and their advertising partners to use past learnings – and, more importantly – ...

UK start-up George Medicines has brought its triple therapy for high blood pressure over the finish line, with an FDA ...

Novo Nordisk's GLP-1 agonist semaglutide, used to treat diabetes and obesity, may cause a serious eye condition that can lead ...

Changing a cultural undertow is one of the hardest leadership challenges in any industry, and perhaps even more so in the ...

Clesrovimab has been held up by MSD (known as Merck & Co in the US and Canada) as offering simpler dosing and better clinical ...

The NHS is reported to be in line for a £30 billion ($40.7 billion) increase to its budget in the UK government's upcoming ...

Otsuka and Vera Therapeutics have both presented new data on drug candidates for IgA nephropathy (IgAN), striving to join a ...

AbbVie presented new data from its novel antibody-drug conjugates (ADCs) at ASCO 2025, including telisotuzumab adizutecan in advanced non-small cell lung cancer, ABBV-706 in high-grade neuroendocrine ...

It is the first fundraising effort at Neuralink since its $280 million Series D round in 2023 and brings the company's total ...

The tantalising development has been reported by researchers at the Peter Doherty Institute for Infection and Immunity in ...

MSD is reported to have been negotiating with Swiss biotech MoonLake Immunotherapeutics over a takeover deal – estimated to ...

The combination of Bayer's mineralocorticoid receptor antagonist (MRA) finerenone and Boehringer Ingelheim and Eli Lilly's ...